Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 6, 2002, Pages 665-671

  Rombouts, S A R B ^a,b   Barkhof, F ^a   Van Meel, C S ^b   Scheltens, P ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DETERIORATION; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; MENTAL TASK; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; PRIORITY JOURNAL; TASK PERFORMANCE; WORKING MEMORY;

AGED; ALZHEIMER DISEASE; ATTENTION; BRAIN MAPPING; CARBAMATES; CEREBRAL CORTEX; CHOLINERGIC FIBERS; CHOLINESTERASE INHIBITORS; FEMALE; FRONTAL LOBE; HUMAN; MAGNETIC RESONANCE IMAGING; MALE; MENTAL RECALL; NERVE NET; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PATTERN RECOGNITION, VISUAL; PREFRONTAL CORTEX; SUPPORT, NON-U.S. GOV'T;

EID: 0036901184     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.6.665     Document Type: Article

References (21)

1. Jann MW. Rivastigmine, a new-generatian cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000;20:1-12.
2. Spencer CM, Noble S. Rivastigmine - A review of its use in Alzheimer's disease. Drug Aging 1998;13:391-411.
3. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). Eur J Neurol 1999;6:423-9.
4. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
5. Morris JC. The clinical dementia rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-14.
6. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
7. Haxby JV, Ungerleider LG, Horwitz B, et al. Face encoding and recognition in the human brain. Proc Acad Natl Sci USA 1996;93:922-7.
8. Kanwisher N, McDermott J, Chun MM. The fusiform face area - A module in human extrastriate cortex specialized for face perception. J Neurosci 1997;17:4302-11.
9. Small SA, Perera GM, DeLaPaz R, et al. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 1999;45:466-72.
10. Braver TS, Cohen JD, Nystrom LE, et al. A parametric study of prefrontal cortex involvement in human working memory. Neuroimage 1997;5:49-62.
11. D'Esposito M, Aguirre GK, Zarahn E, et al. Functional MRI studies of spatial and nonspatial working memory. Cognitive Brain Research 1998;7:1-13.
12. Friston KJ, Holmes AP, Worsley KJ, et al. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapping 1995;2:189-210.
13. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Stuttgart: Thieme Verlag, 1988.
14. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002;15:870-8.
15. Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 2000;290:2315-19.
16. Sperling R, Greve D, Dale A, et al. Functional MRI detection of pharmacologically induced memory impairment. Proc Acad Natl Sci USA 2002;99:455-60.
17. Cohen JD, Forman SD, Braver TS, et al. Activation of the prefrontal cortex in a nanspatial working memory task with functional MRI. Hum Brain Mapping 1994;1:293-304.
18. Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997;49:786-94.
19. Boron JC, Chetelat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001;14:298-309.
20. Rombouts SARB, Barkhof F, Witter MP, et al. Unbiased whole-brain analysis of gray matter lass in Alzheimer's disease. Neurosci Lett 2000;285:231-3.
21. Rosler M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 2001;322:1456.